Viral hepatitis

Lutasun is an effective agent in treatment of the patients with viral hepatitis

The improvement rates of clinical symptoms and signs of the treatment group are significantly higher than those of control group. The differences are statistically significant.

The recovery rates of ALT, AST, TBIL, A/G of the treatment group are significantly higher than those of control group. The differences are statistically significant.

96 patients were randomly divided into 2 groups. 46 patients as a control group were given conventional treatment. 50 patients as a treatment group were administered Lutasun 1.8 g·d-1 iv for 1 month on base of conventional treatment. After the therapy, the clinical symptoms and liver function in the treatment group was greatly improved compared with that in the control group, with general effective rate 90.0% and 54.3% respectively. No side effect was observed.

Reference: Luan Ling, et al. Clinical efficacy of Atomolan in treatment of the patients with virus hepatits[J]. Chinese Journal Of Clinical Pharmacology and Therapeutics, 2003, 8 (3): 351-353.